Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Current Leases (2019 - 2025)

Plus Therapeutics (PSTV) has disclosed Current Leases for 7 consecutive years, with $21000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases fell 69.12% to $21000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $21000.0, a 69.12% decrease, with the full-year FY2024 number at $44000.0, down 63.33% from a year prior.
  • Current Leases was $21000.0 for Q3 2025 at Plus Therapeutics, down from $30000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $127000.0 in Q2 2021 to a low of $21000.0 in Q3 2025.
  • A 5-year average of $89882.4 and a median of $107000.0 in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: rose 9.35% in 2023, then plummeted 69.12% in 2025.
  • Plus Therapeutics' Current Leases stood at $106000.0 in 2021, then increased by 3.77% to $110000.0 in 2022, then increased by 9.09% to $120000.0 in 2023, then plummeted by 63.33% to $44000.0 in 2024, then crashed by 52.27% to $21000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Current Leases are $21000.0 (Q3 2025), $30000.0 (Q2 2025), and $40000.0 (Q1 2025).